Is It Time for New Thinking About High-Density Lipoprotein?

Is It Time for New Thinking About High-Density Lipoprotein?
Madsen, Christian M.; Nordestgaard, Børge G.
2018-03-01 00:00:00
Editorial Is It Time for New Thinking About High-Density Lipoprotein? Christian M. Madsen, Børge G. Nordestgaard he perception of high-density lipoprotein (HDL) choles- mortality with high HDL cholesterol because neither cardio- Tterol as the good cholesterol that protects against athero- vascular nor cancer mortality was increased with high HDL sclerotic cardiovascular disease (ASCVD) has persisted for cholesterol. The main strength of the study is the large num- decades based largely on the countless observational studies ber of included individuals from the general population with showing high risk of ASCVD in individuals with low concen- long-term follow-up. The main limitations include the inher- trations of HDL cholesterol. The notion has been the higher ent inability of observational studies to address the question the better and the faith in HDL cholesterol–elevating drugs of causality and the lack of included information on additional as a new treatment option for ASCVD so great, that >70 000 lipid biomarkers, such as triglycerides, which are inversely patients worldwide have been randomized in phase III out- associated with HDL cholesterol. Two main questions arise from this and the recent similar come trials with the 4 major cholesteryl ester transfer pro- 2–5 14–16 tein inhibitors. Cholesteryl ester
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngArteriosclerosis, Thrombosis, and Vascular BiologyWolters Kluwer Healthhttp://www.deepdyve.com/lp/wolters-kluwer-health/is-it-time-for-new-thinking-about-high-density-lipoprotein-Ht25N4R2BP

Abstract

Editorial Is It Time for New Thinking About High-Density Lipoprotein? Christian M. Madsen, Børge G. Nordestgaard he perception of high-density lipoprotein (HDL) choles- mortality with high HDL cholesterol because neither cardio- Tterol as the good cholesterol that protects against athero- vascular nor cancer mortality was increased with high HDL sclerotic cardiovascular disease (ASCVD) has persisted for cholesterol. The main strength of the study is the large num- decades based largely on the countless observational studies ber of included individuals from the general population with showing high risk of ASCVD in individuals with low concen- long-term follow-up. The main limitations include the inher- trations of HDL cholesterol. The notion has been the higher ent inability of observational studies to address the question the better and the faith in HDL cholesterol–elevating drugs of causality and the lack of included information on additional as a new treatment option for ASCVD so great, that >70 000 lipid biomarkers, such as triglycerides, which are inversely patients worldwide have been randomized in phase III out- associated with HDL cholesterol. Two main questions arise from this and the recent similar come trials with the 4 major cholesteryl ester transfer pro- 2–5 14–16 tein inhibitors. Cholesteryl ester